All In Biotech

Drug Trial Radar · NCT01199263

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin NSC # 729968) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Last checked: Nov 19, 2026Latest source record: Sep 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

108

Actual

Start

Dec 6, 2010

Primary completion

Jun 1, 2015

Study completion Jul 17, 2020

Sponsor

Sponsor type
NIH
Collaborators
NRG Oncology
First posted
Sep 10, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase II trial studies the side effects and how well giving paclitaxel with or without viral therapy works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Viral therapy may be able to kill tumor cells without damaging normal cells. Giving paclitaxel together with viral therapy may kill more tumor cells.

Conditions

  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma

Interventions

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PaclitaxelDrug

    Given IV

  • PelareorepBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Approximately 4.5 years.
  2. Number of Participants With Adverse Events Grade 3 or Greater as Assessed by CTCAE Version 4.0Time frame: approximately 4.5 years

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut

  • Northeast Georgia Medical Center-Gainesville

    Gainesville, Georgia

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho

  • Indiana University/Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana

  • Michigan Cancer Research Consortium NCORP

    Ann Arbor, Michigan

  • Saint Joseph Mercy Hospital

    Ann Arbor, Michigan

  • Beaumont Hospital - Dearborn

    Dearborn, Michigan

  • Ascension Saint John Hospital

    Detroit, Michigan

  • Hurley Medical Center

    Flint, Michigan

  • Genesys Regional Medical Center

    Grand Blanc, Michigan

  • Allegiance Health

    Jackson, Michigan

  • Sparrow Hospital

    Lansing, Michigan

  • Saint Mary Mercy Hospital

    Livonia, Michigan

  • Saint Joseph Mercy Oakland

    Pontiac, Michigan

  • Lake Huron Medical Center

    Port Huron, Michigan

  • Ascension Saint Mary's Hospital

    Saginaw, Michigan

  • Saint John Macomb-Oakland Hospital

    Warren, Michigan

  • Mayo Clinic in Rochester

    Rochester, Minnesota

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Women's Cancer Center of Nevada

    Las Vegas, Nevada

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico

  • Atrium Health Cabarrus/LCI-Concord

    Concord, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Case Western Reserve University

    Cleveland, Ohio

  • Cleveland Clinic Cancer Center/Fairview Hospital

    Cleveland, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Hillcrest Hospital Cancer Center

    Mayfield Heights, Ohio

  • UH Seidman Cancer Center at Lake Health Mentor Campus

    Mentor, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Women and Infants Hospital

    Providence, Rhode Island

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas

  • Carilion Clinic Gynecological Oncology

    Roanoke, Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.